Drug Chatter -- Tracking biopharma stock chatter

DrugPatentWatch - Biopharmaceutical Business Intelligence

Profile for Acceleron Pharma Inc. (XLRN)

« Back to company index

XLRN Chatter Timeline

Stock Ticker for XLRN

Most Active Tweeters for XLRN

UserTweets
@AmericanBanking 9
@bulletin_en 8
@OlympiaReport 7
@TheMarketsDaily 4
@WeekHerald 3

Recent Tweets for XLRN

bulletin_en @bulletin_en
LogicBio Therapeutics Inc. $XLRN Comparing side by side https://t.co/MBT8GTlSh5
May 23rd 2019, 8:05pm
bulletin_en @bulletin_en
Seelos Therapeutics Inc. $XLRN Contrasting side by side https://t.co/J7Jp7VyoVq
May 23rd 2019, 5:05pm
IlliniJJ @IlliniJJ
$XLRN starting to wake up with a couple of 2H 2019 read outs: https://t.co/CNO3ZgB6Rm
May 22nd 2019, 3:05pm
ConsumerFeed @ConsumerFeed
Zacks Investment Research Lowers Acceleron Pharma $XLRN to Hold https://t.co/6j7W4NYTiM
May 21st 2019, 2:05am
AmericanBanking @AmericanBanking
$27.14 Million in Sales Expected for Acceleron Pharma Inc $XLRN This Quarter https://t.co/iRwg6x8uZK #stocks
May 21st 2019, 1:05am
dispatchtribune @dispatchtribune
Acceleron Pharma $XLRN Lowered to “Hold” at Zacks Investment Research https://t.co/sdzQ2Q7KQ3
May 20th 2019, 5:05am
AmericanBanking @AmericanBanking
Brokerages Expect Acceleron Pharma Inc $XLRN Will Announce Earnings of -$0.23 Per Share https://t.co/xbLEjyZ7y5 #stocks
May 20th 2019, 12:05am
OlympiaReport @OlympiaReport
Acceleron Pharma $XLRN Cut to “Hold” at Zacks Investment Research https://t.co/cRAWZZxvaF
May 18th 2019, 2:05pm
bulletin_en @bulletin_en
Contrasting of Arcus Biosciences Inc. $XLRN https://t.co/Tb5vY2BIa6
May 18th 2019, 1:05pm
dailypoliticaln @dailypoliticaln
Acceleron Pharma $XLRN Downgraded by Zacks Investment Research https://t.co/msuILRo9I1
May 17th 2019, 3:05pm
ThisLincolnian @ThisLincolnian
Acceleron Pharma $XLRN Price Target Increased to $69.00 by Analysts at HC Wainwright https://t.co/FDnqR88zdy
May 17th 2019, 2:05am
WeekHerald @WeekHerald
Acceleron Pharma $XLRN Price Target Increased to $69.00 by Analysts at HC Wainwright https://t.co/ZCuM2jiwOU
May 17th 2019, 2:05am
OlympiaReport @OlympiaReport
Acceleron Pharma $XLRN Price Target Increased to $69.00 by Analysts at HC Wainwright https://t.co/73AEAiVKFO
May 17th 2019, 2:05am
macondailynews @macondailynews
HC Wainwright Raises Acceleron Pharma $XLRN Price Target to $69.00 https://t.co/lfPvXydtBu
May 16th 2019, 5:05am
bbnsnews @bbnsnews
Acceleron Pharma $XLRN Rating Reiterated by Cowen https://t.co/BiwBOw2qLo
May 16th 2019, 2:05am
bulletin_en @bulletin_en
Reviewing DelMar Pharmaceuticals Inc. $XLRN's results https://t.co/vKHdwKu2DV
May 15th 2019, 10:05pm
AmericanBanking @AmericanBanking
Acceleron Pharma $XLRN – Analysts’ Weekly Ratings Updates https://t.co/bYbCcwkp1s #stocks
May 15th 2019, 6:05am
OlympiaReport @OlympiaReport
Acceleron Pharma $XLRN – Analysts’ Weekly Ratings Updates https://t.co/Gks6SnMJqN
May 15th 2019, 6:05am
OlympiaReport @OlympiaReport
Acceleron Pharma $XLRN Rating Reiterated by Cowen https://t.co/uihYK7hRsr
May 15th 2019, 4:05am
TheMarketsDaily @TheMarketsDaily
Acceleron Pharma $XLRN PT Raised to $69.00 at HC Wainwright https://t.co/2A1efZQju0
May 15th 2019, 4:05am
bulletin_en @bulletin_en
Reviewing AnaptysBio Inc. $XLRN's results https://t.co/JoVwrPBrsk
May 15th 2019, 3:05am
AcceleronPharma @AcceleronPharma
Save the date! $XLRN will be presenting at the @UBS Global Healthcare Conference on 5/20 at 11am EDT. Webcast detai… https://t.co/OY6P7EoM1p
May 14th 2019, 7:05am
TickerReport @TickerReport
Piper Jaffray Companies Reiterates “Overweight” Rating for Acceleron Pharma $XLRN https://t.co/jLSReyyQzB
May 14th 2019, 5:05am
dailypoliticaln @dailypoliticaln
Piper Jaffray Companies Reiterates “Overweight” Rating for Acceleron Pharma $XLRN https://t.co/2ejaex5CbZ
May 14th 2019, 5:05am
ZolmaxNews @ZolmaxNews
Piper Jaffray Companies Reiterates “Overweight” Rating for Acceleron Pharma $XLRN https://t.co/BhgUQIpL5v
May 14th 2019, 5:05am
WKRBNews @WKRBNews
Acceleron Pharma $XLRN Given Buy Rating at Cowen https://t.co/V5SG2XcWYB #markets
May 14th 2019, 5:05am
OlympiaReport @OlympiaReport
Acceleron Pharma Inc $XLRN to Post FY2022 Earnings of $1.60 Per Share, Piper Jaffray Companies Forecasts https://t.co/LBFVr0CFkl
May 14th 2019, 4:05am
TickerReport @TickerReport
Acceleron Pharma $XLRN Upgraded by BidaskClub to Sell https://t.co/UP5V6kBIPt
May 14th 2019, 2:05am
dailypoliticaln @dailypoliticaln
Acceleron Pharma $XLRN Upgraded by BidaskClub to Sell https://t.co/HIn8F1Hvxt
May 14th 2019, 2:05am
WatchlistN @WatchlistN
Acceleron Pharma $XLRN Upgraded by BidaskClub to Sell https://t.co/vwJ8BEdJMt
May 14th 2019, 2:05am
bulletin_en @bulletin_en
Bellicum Pharmaceuticals Inc. $XLRN https://t.co/Pb3h8yrmNU
May 13th 2019, 7:05pm
AmericanBanking @AmericanBanking
HC Wainwright Raises Acceleron Pharma $XLRN Price Target to $69.00 https://t.co/HPm1mWdA0t #stocks
May 13th 2019, 6:05pm
ThisLincolnian @ThisLincolnian
Acceleron Pharma $XLRN Rating Reiterated by Cowen https://t.co/D5d4dZotOt
May 13th 2019, 10:05am
OlympiaReport @OlympiaReport
Acceleron Pharma’s $XLRN “Overweight” Rating Reiterated at Piper Jaffray Companies https://t.co/utirMveApE
May 13th 2019, 8:05am
AmericanBanking @AmericanBanking
Acceleron Pharma Inc $XLRN Expected to Earn FY2022 Earnings of $1.60 Per Share https://t.co/90oycgUwVD #stocks
May 13th 2019, 4:05am
OlympiaReport @OlympiaReport
Acceleron Pharma $XLRN Upgraded at BidaskClub https://t.co/s4rBzJuiVS
May 13th 2019, 3:05am
WeekHerald @WeekHerald
Acceleron Pharma $XLRN Upgraded at BidaskClub https://t.co/ecYAnmTDFU
May 13th 2019, 3:05am
ThisLincolnian @ThisLincolnian
Acceleron Pharma $XLRN Upgraded to “Sell” at BidaskClub https://t.co/sUAnF55pdd
May 13th 2019, 3:05am
TheMarketsDaily @TheMarketsDaily
Cowen Reaffirms Buy Rating for Acceleron Pharma $XLRN https://t.co/9jHqhg2Fef
May 12th 2019, 2:05pm
AmericanBanking @AmericanBanking
Acceleron Pharma’s $XLRN Buy Rating Reaffirmed at Cowen https://t.co/uZeaGIkbaK #stocks
May 12th 2019, 2:05pm
bulletin_en @bulletin_en
Acceleron Pharma $XLRN Shareholder Perceptive Advisors Has Cut Holding by $27.42 Million as Market Value Declined;… https://t.co/lgxIDBunJy
May 12th 2019, 11:05am
stocknewstimes @stocknewstimes
Acceleron Pharma $XLRN Given “Overweight” Rating at Piper Jaffray Companies https://t.co/xxJrD59Azp
May 12th 2019, 10:05am
SleekMoneycom @SleekMoneycom
Acceleron Pharma $XLRN Given “Overweight” Rating at Piper Jaffray Companies https://t.co/8pL7B8gk9E #investing
May 12th 2019, 10:05am
TheMarketsDaily @TheMarketsDaily
Acceleron Pharma $XLRN Upgraded to “Sell” by BidaskClub https://t.co/TBG7eBX0Fo
May 12th 2019, 2:05am
intercooleronli @intercooleronli
Acceleron Pharma $XLRN Cut to “Buy” at ValuEngine https://t.co/8J8NGskQLI #investingnews
May 12th 2019, 12:05am
ledgerzette @ledgerzette
Acceleron Pharma $XLRN Cut to “Buy” at ValuEngine https://t.co/4OIVJeZceO #stocks
May 12th 2019, 12:05am
macondailynews @macondailynews
Acceleron Pharma’s $XLRN “Overweight” Rating Reiterated at Piper Jaffray Companies https://t.co/aUmnbKeZoP
May 11th 2019, 3:05pm
WatchlistN @WatchlistN
Acceleron Pharma $XLRN Posts Earnings Results, Misses Expectations By $0.07 EPS https://t.co/2Lfmrv8Kse
May 11th 2019, 10:05am
AmericanBanking @AmericanBanking
Acceleron Pharma Inc $XLRN Given Consensus Recommendation of “Buy” by Brokerages https://t.co/jEJ2POJ2OD #stocks
May 11th 2019, 7:05am
stocknewstimes @stocknewstimes
Acceleron Pharma $XLRN Upgraded to “Sell” at BidaskClub https://t.co/DzRzr31tkY
May 11th 2019, 12:05am

DrugPatentWatch - Make Better Decisions
Contact © thinkBiotech LLC 2004 - 2019. All rights reserved.